In particular, we suggest that agonists of the human β3-AR, such as mirabegron,44 already used to treat an overactive bladder, may either improve the impaired concentrating ability of the kidney or increase the beneficial effects of the current XNDI therapy. This evidence concerns the gene ADRB3 and overactive bladder.